nach oben

Rheumatology International

Erschienen in:

01.03.2006 | Original Article

Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis

verfasst von: S. Andereya, N. Streich, B. Schmidt-Rohlfing, T. Mumme, R. Müller-Rath, U. Schneider

Erschienen in: Rheumatology International | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Numerous studies have focused on the significance of modern marker proteins in the synovial fluid of the knee joint and in the serum both, for osteoarthritis (OA) and rheumatoid arthritis (RA). The relationship between the serum concentrations and the concentrations in the synovial fluid is still unclear. Synovial fluid and serum samples were obtained from 13 patients with advanced OA and from 8 patients with severe RA and concentrations of MMP-1, MMP-3, MMP-13, TIMP-1, COMP and MIA/CD-RAP were determined. All values were normalized against the total protein concentrations. Serum concentrations of MMP-13 in the RA-group were statistically higher than the synovial values (P<0.05). MMP-13 was the only marker protein that revealed distinct higher levels in the serum than in the synovial fluid. The study design allows only conclusions about advanced stages of RA and OA. Longitudinal investigations may provide further information about the value of MMP-13 as a potential marker to monitor the course of RA and OA.

Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–461PubMedCrossRef

Firestein GS (1996) Etiology and pathogenesis of rheumatoid arthritis. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) The textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 851–897

Nagase H, Okada Y (1995) Proteinases and matrix degradation. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) The textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 323–341

Nagase H, Woessner JF Jr (1993) Role of endogenous proteinases in the degradation of cartilage matrix. In: Woessner JF Jr, Howell DS (eds) Joint cartilage degradation. Marcel Dekker, New York, pp 159–185

Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE (1996) Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271:30375–30380PubMedCrossRef

Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed

Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C (1994) Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091–2094PubMed

Neidel J, Schulze M, Sova L, Lindschau J (1996) Practical significance of cytokine determination in joint fluid in patients with arthroses or rheumatoid arthritis. Z Orthop Ihre Grenzgeb 134:381–385PubMedCrossRef

MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI (1990) Discoordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergetic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238–17245PubMed

10.

Martell Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP (1994) Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthrosis and rheumatoid arthritis. Lab Invest 70:807–815

11.

Mauviel A (1993) Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53:288–295PubMedCrossRef

12.

Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE (1993) The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP) and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 36:372–379PubMedCrossRef

13.

Shinmei M, Kobayashi T, Yoshihara Y, Samura A (1995) Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. J Rheumatol Suppl 43:78–81PubMed

14.

Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969–975PubMedCrossRef

15.

Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583–591PubMedCrossRef

16.

Marti C, Neidhart M, Gerber T, Hauser N, Michel BA, Hauselmann HJ (1999) Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis. Z Rheumatol 58:79–87PubMedCrossRef

17.

Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K (2002) Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10:707–713PubMedCrossRef

18.

Bosserhoff AK, Buettner R (2002) Expression, function and clinical relevance of MIA (melanoma inhibiting activity). Histol Histopathol 17:289–300PubMed

19.

Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W., Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–3153PubMed

20.

Wagner V, Rudi J, Naher H, Stremmel W (2000) Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Med Oncol 17:35–38PubMedCrossRef

21.

Müller-Ladner U, Bosserhoff AK, Dreher K, Hein R, Neidhart M, Gay S, Scholmerich J, Buettner R, Lang B (1999) MIA (melanoma inhibitory activity): a potentional serum marker for rheumatoid arthritis. Rheumatology 38:148–154PubMedCrossRef

22.

Schmidt-Rohlfing B, Schneider U, Thomsen M, Bosserhoff AK (2002) Correlation of a novel matrix protein with the degree of cartilage degradation. Rheumatol Int 22:165–169PubMedCrossRef

23.

Lohmander LS, Dahlberg L, Ryd L, Heinegard D (1989) Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 32:1434–1442PubMedCrossRef

24.

Schmidt-Rohlfing B, Gavenis K, Kippels M, Schneider U (2002) New potential markers for cartilage degradation of the knee joint. Scand J Rheumatol 31:151–157PubMedCrossRef

25.

Väätäinen U, Lohmander LS, Thonar E, Hongisto T, Agren U, Rönkkö S, Jaroma H, Kosma VM, Tammi M, Kiviranta I (1998) Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patella. Osteoarthritis Cartilage 6:115–124PubMedCrossRef

26.

Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L (2001) Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 44:2777–2789PubMedCrossRef

27.

Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T (2002) Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 46:2648–2657PubMedCrossRef

28.

Bluteau G, Conrozier T, Mathieu P, Vignon E, Herbage D, Mallein-Gerin F (2001) Matrix metalloproteinase-1, −3, −13 and aggrecanase-1 and −2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta 1526:147–158PubMed

29.

Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B (2001) Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum 44:2263–2274PubMedCrossRef

30.

Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR (2001) Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 44:2503–2511PubMedCrossRef

31.

Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2002) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology (Oxford) 41:78–87CrossRef

32.

Bramono DS, Richmond JC, Weitzel PP, Kaplan DL, Altman GH (2004) Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res 428:272–285PubMedCrossRef

33.

Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geohegan KF, Hambor JE (1996) Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. Clin Invest 97:761–768

34.

Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C (1997) Matrix metalloproteinase 13 (Collagenase 3) in human rheumatoid synovium. Arthritis Rheum 40:1391–1399PubMedCrossRef

35.

Gay S, Gay RE, Koopman WJ (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction. Ann Rheum Dis 52:839–847CrossRef

36.

Gay S, Gay RE (1989) Cellular basis and oncogene expression of rheumatoid joint destruction. Rheumatol Int 9:105–113PubMed

37.

Zvaifler NJ, Tsai V, Alsalameh S, von Kempis J, Firestein G, Lotz M (1997) Pannocytes: distinctive cells found in rheumatoid arthritis cartilage erosions. Am J Pathol 150:1125–1138PubMed

Titel: Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis
verfasst von: S. Andereya
N. Streich
B. Schmidt-Rohlfing
T. Mumme
R. Müller-Rath
U. Schneider
Publikationsdatum: 01.03.2006
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 5/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-005-0006-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

Catalase and PPARγ2 genotype and risk of rheumatoid arthritis in Koreans

Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial?

Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases

Nocardiosis in a patient with primary anti-phospholipid syndrome

Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus